Clinical Trials@2x
  • News

    Most Read

    • Montreal Heart Institute reports positive results from Covid-19 trial
    • Telemedicine to benefit the most from remote patient monitoring tools: Poll
    • NIH reports full-dose blood thinners improve Covid-19 outcome

    Most Recent

    Clinical Trials

    Montreal Heart Institute reports positive results from Covid-19 trial

    25 Jan 2021
  • Analysis

    Sections

    • Features
    • Comment
    • Projects

    Most Read

    • Biogen’s Spinraza set to increase its chances to maintain a strong position in spinal muscular atrophy
    • Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market
    • Novo Nordisk’s makes strides into Alzheimer’s with anti-diabetic drug

    Most Recent

    Clinical Trials

    Biogen’s Spinraza set to increase its chances to maintain a strong position in spinal muscular atrophy

    12 Jan 2021
  • Sectors

    Sections

    • Clinical Trials
    • Approvals
    • Clinical Research
    • Operations
    • Outsourcing
    • Supply Chain
    • Cold Chain
    • Data Management
    • Medical Devices

    Most Read

    • Montreal Heart Institute reports positive results from Covid-19 trial
    • Phase II Trial of Anti-Amyloid AR1001 Signals Little Promise for Patients with Alzheimer’s Disease
    • Telemedicine to benefit the most from remote patient monitoring tools: Poll

    Most Recent

    Clinical Trials

    Montreal Heart Institute reports positive results from Covid-19 trial

    25 Jan 2021
  • Themes
  • Deals

    Most Read

    • Investment firm GI Partners closes Clinical Ink acquisition
    • Investment firm GI Partners to acquire minority interest in Clinical Ink
    • IVI and SNU partner to trial Inovio’s Covid-19 vaccine in Korea

    Most Recent

    Clinical Trials

    Investment firm GI Partners closes Clinical Ink acquisition

    27 Aug 2020
  • Companies

    Sections

    • Company A-Z
    • Company Categories
    • Products & Services
    • Company Releases
    • White Papers
    • Videos

    Most Read

    • Linari NanoTech
    • OpenClinica
    • Strategikon Pharma

    Most Recent

    Linari NanoTech

    19 Jan 2021
  • Magazine
  • Events
Menu
  • News
  • Analysis
    • Features
    • Comment
    • Projects
  • Investment
  • Sectors
    • Clinical Trials
    • Approvals
    • Clinical Research
    • Operations
    • Outsourcing
    • Supply Chain
    • Cold Chain
    • Data Management
    • Medical Devices
  • Deals
  • Tech
  • Disruption
  • Coronavirus
Partners
  • Accelerating Clinical Trials
  • Simplifying Clinical Trials
Tools
  • Companies
    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos
  • Awards
  • Events
  • Magazine
The Company
  • About Us
  • Contact Us
  • Advertise With Us
  • Visit GlobalData
  • Login
  • Register
  • Login
  • Register
Calliditas enrols first patient in Phase III study of Nefecon

Calliditas enrols first patient in Phase III study of Nefecon

Calliditas Therapeutics has enrolled the first patient in a pivotal Phase III NEFIGARD clinical trial...

14th November 2018

Latest News

Clinical Trials

Montreal Heart Institute reports positive results from Covid-19 trial

25 Jan 2021
Technology

Telemedicine to benefit the most from remote patient monitoring tools: Poll

25 Jan 2021
Clinical Trials

NIH reports full-dose blood thinners improve Covid-19 outcome

25 Jan 2021
Clinical Trials

Senhwa Biosciences initiates enrolment in Covid-19 drug trial

25 Jan 2021

Company A-Z

View All

Company Releases

View All

White Papers

View All

Videos

View All
CTArena_white-logo_

Powered by Pharma Tech Logo

  • About Us
  • Editorial Approach
  • Contact Us
  • Terms and Conditions
  • Privacy Policy

© Copyright 2021 Verdict Media Limited.

  • Lost Password Back ⟶
  • Login
  • Register
Lost Password?
Registration is disabled.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more